Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7703195 | 1.00 | MEN1 (0.42) | MEN1KMT2ACYP3A4ALOX15KDM4E | |
| SCHEMBL28476303 | 0.92 | ALOX15 (0.42) | MEN1KMT2ACYP3A4ALOX15KDM4E | |
| SCHEMBL17822155 | 0.89 | MEN1 (0.40) | MEN1KMT2ACYP3A4ALOX15KDM4E | |
| Pentanal SCHEMBL20856850 | 0.83 | TSHR (0.45) | MEN1KMT2ACYP3A4ALOX15KDM4E | |
| SCHEMBL27509626 | 0.83 | — | — | |
| SCHEMBL16357610 | 0.82 | ALDH1A1 (0.50) | MEN1KMT2ACYP3A4ALOX15KDM4E | |
| SCHEMBL5306831 | 0.82 | MEN1 (0.39) | MEN1KMT2ACYP3A4ALOX15KDM4E | |
| SCHEMBL464975 | 0.82 | MEN1 (0.39) | MEN1KMT2ACYP3A4ALOX15KDM4E | |
| SCHEMBL5604094 | 0.82 | MEN1 (0.39) | MEN1KMT2ACYP3A4ALOX15KDM4E | |
| SCHEMBL94185 | 0.82 | MEN1 (0.39) | MEN1KMT2ACYP3A4ALOX15KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10450532-B2 | Organic compounds and their use as fragrance ingredients | GIVAUDAN S.A. (CH) | 2019-10-22 | — | — | US | claimed |
| US-20170327769-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS AND THEIR USE AS FRAGRANCE INGREDIENTS | GIVAUDAN S.A. (CH) | 2017-11-16 | — | — | US | claimed |
| EP-3230245-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS AND THEIR USE AS FLAGRANCE INGREDIENTS | Givaudan SA (CH) | 2017-10-18 | — | — | EP | claimed |
| EP-3149135-A2 | PERFUME COMPOSITIONS | Givaudan S.A. (CH) | 2017-04-05 | — | — | EP | claimed |
| US-20170073614-A1 | Perfume Compositions | GIVAUDAN SA (CH) | 2017-03-16 | — | — | US | claimed |
| WO-2016091895-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS AND THEIR USE AS FLAGRANCE INGREDIENTS | GIVAUDAN SA (CH) | 2016-06-16 | — | — | WO | claimed |
| WO-2015181257-A2 | PERFUME COMPOSITIONS | GIVAUDAN SA (CH) | 2015-12-03 | — | — | WO | claimed |
| CN-111836667-B | Improvements in or relating to organic compounds | 奇华顿股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| US-20230287297-A1 | Perfume Compositions | GIVAUDAN SA (CH) | 2023-09-14 | — | — | US | disclosed |
| US-11639484-B2 | Perfume compositions | GIVAUDAN SA (CH) | 2023-05-02 | — | — | US | disclosed |
| CN-114340775-A | Improvements in or relating to organic compounds | 奇华顿股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-111527191-B | Encapsulated perfume compositions and methods of making same | 奇华顿股份有限公司 | 2021-12-31 | — | — | CN | disclosed |
| CN-113853192-A | Core-shell encapsulated compositions comprising benefit agents | 奇华顿股份有限公司 | 2021-12-28 | — | — | CN | disclosed |
| EP-1931324-A2 | DES-C,D ANALOGS OF 1ALPHA,25-DIHYDROXY-19-NORVITAMIN D3 | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-06-18 | — | — | EP | disclosed |
| US-20070112077-A1 | Des-C,D analogs of 1alpha,25-dihydroxy-19-norvitamin D3 | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2007-05-17 | — | — | US | disclosed |
| WO-2007028000-A2 | DES-C,D ANALOGS OF 1ALPHA,25-DIHYDROXY-19-NORVITAMIN D3 | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-03-08 | — | — | WO | disclosed |
| EP-0983221-B1 | CYCLOHEXANEDIOL DERIVATIVES | BASILEA PHARMACEUTICA AG (CH) | 2002-04-03 | — | — | EP | disclosed |
| EP-0983221-A1 | CYCLOHEXANEDIOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-03-08 | — | — | EP | disclosed |
| US-5969190-A | TREATING HYPERPROLIFERATIVE SKIN DISEASES | HOFFMANN-LA ROCHE INC. (US) | 1999-10-19 | — | — | US | disclosed |
| WO-1998052894-A1 | CYCLOHEXANEDIOL DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450532-B2 | Organic compounds and their use as fragrance ingredients | C9, C5, HRH1 | MEN1 1500/4885KMT2A 2128/4885CYP3A4 567/4885 |
| US-20070112077-A1 | Des-C,D analogs of 1alpha,25-dihydroxy-19-norvitamin D3 | CYP24A1, VDR, CYP2R1 | MEN1 279/4885KMT2A 4855/4885CYP3A4 367/4885 |
| US-20170327769-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS AND THEIR USE AS FRAGRANCE INGREDIENTS | C5, C9, DHCR24 | MEN1 965/4885KMT2A 2438/4885CYP3A4 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.